From the site of the 2025 Innovative Drug High Quality Development Conference held today, we learned that the much-anticipated 1,000,000 CAR-T cell therapy — Fosun Kerry's Akilensis injection, Pharmacomingjunuo's Rikiolensis injection, Syngen Biotech's nakiolensis injection, Reindeer Biologicalex injection, and Kaixing Life Technology's Zevokiolensis injection were all included in the first batch of commercial insurance innovative drug catalogs. This year, all 5 CAR-T models, including Achilensis injections from Fosun Kerry, a subsidiary of Fosun Pharmaceuticals, and Rickie Orense injections, passed the review in the form of a commercial insurance innovative drug catalogue. Previously, CAR-T broke down health insurance negotiations four times.

Zhitongcaijing · 2d ago
From the site of the 2025 Innovative Drug High Quality Development Conference held today, we learned that the much-anticipated 1,000,000 CAR-T cell therapy — Fosun Kerry's Akilensis injection, Pharmacomingjunuo's Rikiolensis injection, Syngen Biotech's nakiolensis injection, Reindeer Biologicalex injection, and Kaixing Life Technology's Zevokiolensis injection were all included in the first batch of commercial insurance innovative drug catalogs. This year, all 5 CAR-T models, including Achilensis injections from Fosun Kerry, a subsidiary of Fosun Pharmaceuticals, and Rickie Orense injections, passed the review in the form of a commercial insurance innovative drug catalogue. Previously, CAR-T broke down health insurance negotiations four times.